Abivax SA Asset Resilience Ratio
Abivax SA asset resilience ratio. Abivax SA (ABVX) has an Asset Resilience Ratio of 2.58% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Abivax SA to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Abivax SA (2013–2025)
Asset resilience ratio of Abivax SA from 2013 to 2025. This chart shows how Abivax SA's Asset Resilience Ratio has changed over time. Read Abivax SA debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Abivax SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Abivax SA total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €14.13 Million | 2.58% |
| Total Liquid Assets | €14.13 Million | 2.58% |
Asset Resilience Insights
- Limited Liquidity: Abivax SA maintains only 2.58% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Abivax SA Industry Peers by Asset Resilience Ratio
Compare Abivax SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Abivax SA Asset Resilience Ratio by Year (2013–2025)
Abivax SA asset resilience ratio by year from 2013 to 2025. The table below shows the annual Asset Resilience Ratio data for Abivax SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.34% | €13.70 Million ≈ $16.01 Million |
€584.34 Million ≈ $683.16 Million |
-40.24pp |
| 2024-12-31 | 42.59% | €87.40 Million ≈ $102.18 Million |
€205.23 Million ≈ $239.93 Million |
+34.28pp |
| 2023-12-31 | 8.30% | €27.16 Million ≈ $31.75 Million |
€327.06 Million ≈ $382.37 Million |
+8.29pp |
| 2022-12-31 | 0.02% | €12.00K ≈ $14.03K |
€73.35 Million ≈ $85.76 Million |
+0.01pp |
| 2021-12-31 | 0.01% | €12.00K ≈ $14.03K |
€110.36 Million ≈ $129.03 Million |
-0.01pp |
| 2020-12-31 | 0.02% | €12.00K ≈ $14.03K |
€71.30 Million ≈ $83.35 Million |
-0.01pp |
| 2019-12-31 | 0.02% | €12.00K ≈ $14.03K |
€51.73 Million ≈ $60.48 Million |
-18.50pp |
| 2018-12-31 | 18.52% | €10.01 Million ≈ $11.71 Million |
€54.05 Million ≈ $63.19 Million |
-37.78pp |
| 2017-12-31 | 56.31% | €30.30 Million ≈ $35.43 Million |
€53.81 Million ≈ $62.92 Million |
+6.64pp |
| 2016-12-31 | 49.67% | €30.10 Million ≈ $35.19 Million |
€60.60 Million ≈ $70.84 Million |
-1.47pp |
| 2015-12-31 | 51.15% | €39.01 Million ≈ $45.60 Million |
€76.27 Million ≈ $89.17 Million |
+46.66pp |
| 2014-12-31 | 4.49% | €1.70 Million ≈ $1.99 Million |
€37.97 Million ≈ $44.39 Million |
+3.45pp |
| 2013-12-31 | 1.04% | €400.00K ≈ $467.64K |
€38.46 Million ≈ $44.97 Million |
-- |
About Abivax SA
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials f… Read more